*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/adverse effects

Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., et al. (2024). Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. Bmj, 385, e078242. http://doi.org/10.1136/bmj-2023-078242